Screening with HPV testing for cervical cancer prevention
The National Screening Unit (NSU) is pleased to be hosting two sessions on the science behind the plan to introduce HPV testing as the primary screening test in the National Cervical Screening Programme in NZ.
The first session will be held in Christchurch on Thursday 13 October 2016 from 5.30 to 7.30 pm, and will be repeated at a second session in Auckland on Friday 14 October 2016 from 12 noon to 3.00 pm.
The sessions will include expert speakers from NZ and Australia, followed by a Q & A panel discussion:
- Dr Jane O’Hallahan, Clinical Director National Screening Unit – Benefits and harms of screening
- Dr Karen Canfell, Director of Research, Cancer Research Division, Cancer Council NSW – The science behind NZ’s decision to change to Primary HPV Testing
- Dr Marion Saville, Chairperson HPV Testing for Primary Screening Project – Compass trial leading the way
- Dr Margaret Sage, Clinical Leader Pathology, National Cervical Screening Programme – The ARTISTIC trial (UK). Putting invasive cancer in perspective
- Dr Gary Fentiman, Clinical Leader Colposcopy, National Cervical Screening Programme – Responding to your concerns.
The sessions are open to everyone with an interest in HPV testing as the primary screening test in the National Cervical Screening Programme.
To attend, please register on the Eventbrite ticket website:
Please feel free to circulate this invitation through your networks as appropriate.